AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33080411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (12.6 mmol of concentrated beetroot juice)
Number of subjects: 12
Study 33080411 — intervention group
Group type: COMPARATOR
Intervention: Nitrate depleted placebo
Number of subjects: 12
Study 33032532 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week physical activity and education program
Number of subjects: 44
Study 33032532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 33545767 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nursing based on Omaha System
Number of subjects: 102
Study 33545767 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing after discharge
Number of subjects: 102
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved cookstove adoption
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Households headed by females
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Private house ownership
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate cooking location
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuel purchasing
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Health benefit perception
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimistic social interaction
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional suitability perception
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Stove use demonstration experience
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheap price perception
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of cookstove
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuel-saving benefit perception
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: More durable stove perception
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational level of head
Number of subjects: 5830
Study 32414323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuel processing requirement
Number of subjects: 5830
Study 35795968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose benzbromarone (LDBen) 25 mg daily
Number of subjects: 196
Study 35795968 — intervention group
Group type: COMPARATOR
Intervention: Low-dose febuxostat (LDFeb) 20 mg daily
Number of subjects: 196
Study 33449799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg once every 2 weeks)
Number of subjects: 854
Study 33449799 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 once every 3 weeks)
Number of subjects: 854
Study 32209396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% yeast hydrolysate
Number of subjects: 240
Study 32209396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% and 3% yeast hydrolysate
Number of subjects: 240
Study 32209396 — intervention group
Group type: COMPARATOR
Intervention: Control (0% yeast hydrolysate)
Number of subjects: 240
Study 34782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3081
Study 34782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3081
Study 34782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-wide dissemination of DPP lifestyle modification
Number of subjects: 3081
Study 34782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-wide metformin therapy
Number of subjects: 3081
Study 33429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice condition (different distances to different goals) in physical execution
Number of subjects: 90
Study 33429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice condition (different distances to different goals) in action observation
Number of subjects: 90
Study 33429362 — intervention group
Group type: COMPARATOR
Intervention: Constant practice condition (fixed distance and goal) in physical execution
Number of subjects: 90
Study 33429362 — intervention group
Group type: COMPARATOR
Intervention: Constant practice condition (fixed distance and goal) in action observation
Number of subjects: 90
Study 33429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 90
Study 33429362 — intervention group
Group type: EXPERIMENTAL
Intervention: No-feedback groups in physical and observational conditions
Number of subjects: 90
Study 32858740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparin (LMWH)
Number of subjects: 27513
Study 32858740 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UH)
Number of subjects: 27513
Study 33793979 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance
Number of subjects: 9475
Study 33793979 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-pay
Number of subjects: 9475
Study 33793979 — intervention group
Group type: EXPERIMENTAL
Intervention: First-quartile NDI (highest deprivation)
Number of subjects: 9475
Study 33793979 — intervention group
Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 9475
Study 32869451 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 5
Study 32869451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 34245288 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 196
Study 34245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral counseling
Number of subjects: 196
Study 34245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Insular lesion presence
Number of subjects: 196
Study 34245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 196
Study 34245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Less dependency
Number of subjects: 196
Study 33596357 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate)
Number of subjects: 770
Study 33596357 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 770
Study 33596357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 33596357 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix monotherapy
Number of subjects: 770
Study 32537887 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 47
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cracked corn (CC: 74% NSC & 9% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ration balancer with low protein (RB-LP: 15% NSC & 17% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ration balancer with high protein (RB-HP: 14% NSC & 37% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NSC pellet (L-NSC: 6% NSC & 12% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam-flaked corn (SF: 73% NSC & 10% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat groats (OG: 64% NSC & 14% CP)
Number of subjects: 18
Study 34053111 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of RB-LP:RB-HP (MIX-P)
Number of subjects: 18
Study 34548555 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular block (group C) with 25 mL of local anesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine)
Number of subjects: 80
Study 34548555 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block (group S) with 25 mL of local anesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine)
Number of subjects: 80
Study 34548555 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular block (group C)
Number of subjects: 80
Study 34548555 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block (group S)
Number of subjects: 80
Study 36521349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 % w/w Liposomal Amphotericin‐B gel
Number of subjects: 45
Study 36521349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % w/w Povidone‐Iodine
Number of subjects: 45
Study 36521349 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal douching
Number of subjects: 45
Study 34144995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering therapy
Number of subjects: 863
Study 33002071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction (SBP target < 120 mmHg)
Number of subjects: 4292
Study 33002071 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP target < 140 mmHg)
Number of subjects: 4292
Study 35785539 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 35785539 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33513546 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 39
Study 33513546 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose (0.24 mL of 24% oral sucrose plus non-nutritive sucking)
Number of subjects: 39
Study 32253895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (AC)
Number of subjects: 24
Study 35253727 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP)
Number of subjects: 22
Study 35253727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (CaGP)
Number of subjects: 22
Study 32077909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation at the time of cataract surgery
Number of subjects: 114
Study 32077909 — intervention group
Group type: COMPARATOR
Intervention: Aphakia (contact lens correction)
Number of subjects: 114
Study 35247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (KEYNOTE-052)
Number of subjects: 0
Study 35247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (KEYNOTE-045)
Number of subjects: 0
Study 35247908 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel/docetaxel/vinflunine) (KEYNOTE-045)
Number of subjects: 0
Study 32216011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 10.0 mg
Number of subjects: 335
Study 32216011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 5.0 mg
Number of subjects: 335
Study 32216011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 35222898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan
Number of subjects: 60
Study 35222898 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 60
Study 33239106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package including simple, accurate diagnostic tests, clinical algorithms, and training and communication.
Number of subjects: 21876
Study 33239106 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control group).
Number of subjects: 21876
Study 35818134 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/Collagen gel
Number of subjects: 20
Study 34800399 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 100
Study 34800399 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 100
Study 34428980 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 320/18/9.6 µg
Number of subjects: 3088
Study 34428980 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 160/18/9.6 µg
Number of subjects: 3088
Study 34428980 — intervention group
Group type: COMPARATOR
Intervention: GFF 18/9.6 µg
Number of subjects: 3088
Study 34428980 — intervention group
Group type: COMPARATOR
Intervention: BFF 320/9.6 µg
Number of subjects: 3088
Study 32444980 — intervention group
Group type: EXPERIMENTAL
Intervention: FSRS plus BEV-based chemotherapy
Number of subjects: 35
Study 32444980 — intervention group
Group type: COMPARATOR
Intervention: BEV-based chemotherapy alone
Number of subjects: 35
Study 32781457 — intervention group
Group type: COMPARATOR
Intervention: 2.5‐mg hypobaric bupivacaine alone
Number of subjects: 90
Study 32781457 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5‐mg hypobaric bupivacaine and 10‐μg fentanyl
Number of subjects: 90
Study 32781457 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5‐mg hypobaric bupivacaine and 0.5‐mg morphine
Number of subjects: 90
Study 34087752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 106
Study 34087752 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based intervention (BMT)
Number of subjects: 106
Study 34087752 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group (QoL)
Number of subjects: 106
Study 35537794 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based mini-app intervention
Number of subjects: 70
Study 35537794 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 33709448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 sentinel node removed
Number of subjects: 190
Study 33709448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sentinel nodes removed
Number of subjects: 190
Study 33709448 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 sentinel nodes removed
Number of subjects: 190
Study 35184123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pachymetry mapping 1 day after DMEK
Number of subjects: 65
Study 33741218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) combined with triamcinolone
Number of subjects: 28
Study 33741218 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone alone
Number of subjects: 28
Study 32048900 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 49
Study 32048900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment plus PSD
Number of subjects: 49
Study 32994242 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (various dosages)
Number of subjects: 2500
Study 32994242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related physical fitness T-score (HPFT)
Number of subjects: 120
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg balance
Number of subjects: 120
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test
Number of subjects: 120
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related physical fitness T-score (HPFT) (highest tertile)
Number of subjects: 120
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg balance (highest tertile)
Number of subjects: 120
Study 35209870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test (highest tertile)
Number of subjects: 120
Study 34207870 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Number of subjects: 80
Study 34207870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy based on antimicrobial susceptibility testing
Number of subjects: 80
Study 33039650 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E and/or 20 μg selenium daily
Number of subjects: 170
Study 33039650 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 170
Study 36184602 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) chemoprophylaxis with an initial 3 day full treatment course followed by twice daily dosing once a week.
Number of subjects: 0
Study 36184602 — intervention group
Group type: EXPERIMENTAL
Intervention: Full 3 day AL treatment course given twice a month.
Number of subjects: 0
Study 36184602 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily treatment given once a week.
Number of subjects: 0
Study 36184602 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 3 day full AL treatment course followed by twice daily dosing once a week.
Number of subjects: 0
Study 33020040 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation Grid (NG)
Number of subjects: 58
Study 33020040 — intervention group
Group type: COMPARATOR
Intervention: No Navigation Grid (Control)
Number of subjects: 58
Study 37318667 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 nm low-level red light (LLRL) irradiation for 6 min daily
Number of subjects: 112
Study 37318667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 32964729 — intervention group
Group type: EXPERIMENTAL
Intervention: DemTect
Number of subjects: 200
Study 34716791 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol olive oil (HPOO) 60 mL/day (320 mg/kg polyphenols)
Number of subjects: 50
Study 34716791 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol olive oil (LPOO) 60 mL/day (86 mg/kg polyphenols)
Number of subjects: 50
Study 32951050 — intervention group
Group type: EXPERIMENTAL
Intervention: AlzRiskMR database
Number of subjects: 1870
Study 32951050 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization (2SMR) analysis methods
Number of subjects: 1870
Study 32660609 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib + trastuzumab + AI
Number of subjects: 198
Study 32660609 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab + AI
Number of subjects: 198
Study 35107389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided repetitive thoracic paravertebral block (TPVB) every 48 hours for a week after antiviral therapy
Number of subjects: 96
Study 35107389 — intervention group
Group type: COMPARATOR
Intervention: Standard antiviral therapy
Number of subjects: 96
Study 35171143 — intervention group
Group type: EXPERIMENTAL
Intervention: Corvis ST (Scheimpflug tonometer)
Number of subjects: 315
Study 33514891 — intervention group
Group type: EXPERIMENTAL
Intervention: UNR844 (1.5%) ophthalmic solution, administered unilaterally twice a day for 7 days, then bilaterally twice a day for 91 days
Number of subjects: 75
Study 33514891 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered unilaterally twice a day for 7 days, then bilaterally twice a day for 91 days
Number of subjects: 75
Study 33514891 — intervention group
Group type: EXPERIMENTAL
Intervention: UNR844 (1.5%) ophthalmic solution
Number of subjects: 75
Study 33514891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 35833956 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 25389
Study 35833956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25389
Study 34124261 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigational template for Salter osteotomy
Number of subjects: 32
Study 34124261 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical method
Number of subjects: 32
Study 32068424 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM_RNT (interpretation training condition with prior activation of RNT)
Number of subjects: 161
Study 32068424 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM_ENH (training condition augmented with positive outcome generation and imagery)
Number of subjects: 161
Study 32068424 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 161
Study 36477733 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 30 mg once daily
Number of subjects: 525
Study 36477733 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg once daily
Number of subjects: 525
Study 34714720 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent high-dose inactivated influenza vaccine (IIV4-HD)
Number of subjects: 1528
Study 34714720 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine (IIV4-SD)
Number of subjects: 1528
Study 34714720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (IIV4-HD and IIV4-SD)
Number of subjects: 1528
Study 32095884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mill Suss™-guided method (Group M: n=36)
Number of subjects: 72
Study 32095884 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided method (Group U: n=36)
Number of subjects: 72
Study 34209476 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional stoves
Number of subjects: 150
Study 34209476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking duration
Number of subjects: 150
Study 34209476 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO guideline limit
Number of subjects: 150
Study 32696396 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 10
Study 32696396 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive treatment
Number of subjects: 10
Study 33741010 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin
Number of subjects: 3694
Study 33754528 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-cm quilting
Number of subjects: 34
Study 33754528 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cm quilting
Number of subjects: 34
Study 33754528 — intervention group
Group type: COMPARATOR
Intervention: non-quilting
Number of subjects: 34
Study 35699175 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided selection of antiplatelet therapy after PCI
Number of subjects: 5276
Study 35699175 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with clopidogrel
Number of subjects: 5276
Study 33450486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-dose esomeprazole (40 mg once a day for 8 weeks)
Number of subjects: 414
Study 33450486 — intervention group
Group type: COMPARATOR
Intervention: Continuous high-dose esomeprazole (40 mg once a day for 8 weeks)
Number of subjects: 414
Study 33450486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-dose esomeprazole
Number of subjects: 414